CX-072 is a PD-L1-targeting Probody therapeutic for the treatment of cancer, currently being evaluated in a Phase 1/2 clinical trial. The study is evaluating CX-072 as monotherapy and in combination with Yervoy® (ipilimumab) or Zelboraf® (vemurafenib) in patients with certain cancers.
Purpose: The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas.
For patients interested in learning if you are eligible for the trial, please visit clinicaltrials.gov.
CX-2009 is a CD166-targeting Probody drug conjugate for the treatment of select advanced cancers and is being studied in a Phase 1/2 clinical trial. The treatment is being evaluated as monotherapy in patients with breast cancer, castration-resistant prostate cancer, cholangiocarcinoma (bile duct cancer), endometrial cancer, head and neck cancer, non-small-cell lung cancer and ovarian cancer.
Purpose: The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors.
For patients interested in learning if you are eligible for the trial, please visit clinicaltrials.gov.